The PROSPER Trial: Chemotherapy-Related Endpoints in Patients with nmCRPC - Neal Shore

(Length of Presentation: 9 min)

Neal Shore, MD, FACS shares his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity and antineoplastic therapies and potentially prolonging overal survival.

Biography:

Neal Shore, MD, FACS